The journal article was titled “Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling in Rat Lung, Blood, and Serum for Assessment of Laser Printer-Emitted Nanoparticle Inhalation Exposure-Induced Disease Risks.”
Her collaborators include researchers from Harvard University, National Institute for Occupational Safety and Health, Nanyang Technological University, Nanjing Medical University, Nanyang Environment & Water Research Institute, and the US Consumer Product Safety Commission.
WVU was appointed to take the lead on the genomic analysis in the collaborative project, leading the research and publishing efforts for the international team in this study.
Focusing on the risks of laser printer emitted nanoparticles (PEPs) through inhalation, the team documented disease risks including adverse cardiovascular dysfunction, metabolic syndrome and neural disorders in both rat lung and blood during exposure. PEPs were also shown to induce genomic changes linked to diabetes, congenital defects, auto-recessive disorders, physical deformation and carcinogenesis.
The article noted that to the best of their knowledge “this is the first study to integrate in vivo, transcriptomics, metabolomics, and lipidomics to assess PEPs inhalation exposure-induced disease risks using a rat model.”
Drugs called triptans are the “mainstay of migraine treatment,” said West Virginia University neurologist Umer Najib, but typically, patients can’t take them more than twice a week. If they have a third migraine, they’re out of luck. But Najib is researching a new way to treat—and prevent—migraine attacks without this limitation: neuromodulation.